| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Veterans | 17 | 2025 | 1750 | 3.650 |
Why?
|
| Brain Injuries, Traumatic | 9 | 2024 | 374 | 3.240 |
Why?
|
| Stress Disorders, Post-Traumatic | 12 | 2024 | 629 | 3.160 |
Why?
|
| Brain Injuries | 20 | 2015 | 763 | 2.890 |
Why?
|
| Depressive Disorder | 23 | 2018 | 456 | 2.560 |
Why?
|
| Stroke | 24 | 2023 | 970 | 2.340 |
Why?
|
| REM Sleep Behavior Disorder | 4 | 2025 | 16 | 2.270 |
Why?
|
| Mood Disorders | 13 | 2015 | 127 | 2.090 |
Why?
|
| Depression | 20 | 2023 | 1243 | 1.760 |
Why?
|
| Transcranial Magnetic Stimulation | 6 | 2017 | 71 | 1.600 |
Why?
|
| Antidepressive Agents | 11 | 2023 | 289 | 1.590 |
Why?
|
| Parkinson Disease | 9 | 2025 | 694 | 1.480 |
Why?
|
| Citalopram | 8 | 2016 | 30 | 1.300 |
Why?
|
| Brain Concussion | 4 | 2019 | 229 | 1.280 |
Why?
|
| Depressive Disorder, Major | 10 | 2017 | 400 | 1.270 |
Why?
|
| Cerebrovascular Disorders | 3 | 2019 | 118 | 1.180 |
Why?
|
| Brain | 15 | 2022 | 2999 | 1.020 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2025 | 5 | 0.970 |
Why?
|
| Prodromal Symptoms | 1 | 2025 | 9 | 0.950 |
Why?
|
| Cognition Disorders | 13 | 2014 | 556 | 0.940 |
Why?
|
| Vagus Nerve Stimulation | 2 | 2022 | 53 | 0.870 |
Why?
|
| Persian Gulf Syndrome | 1 | 2023 | 15 | 0.860 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2022 | 3573 | 0.810 |
Why?
|
| Cerebral Cortex | 7 | 2017 | 449 | 0.790 |
Why?
|
| Mental Disorders | 6 | 2018 | 823 | 0.750 |
Why?
|
| Aged | 51 | 2025 | 19386 | 0.750 |
Why?
|
| Humans | 108 | 2025 | 124263 | 0.740 |
Why?
|
| Male | 76 | 2025 | 60883 | 0.730 |
Why?
|
| Psychiatric Status Rating Scales | 23 | 2020 | 809 | 0.710 |
Why?
|
| Middle Aged | 48 | 2025 | 26366 | 0.700 |
Why?
|
| Blast Injuries | 2 | 2018 | 58 | 0.690 |
Why?
|
| Armed Conflicts | 1 | 2020 | 8 | 0.680 |
Why?
|
| Parasomnias | 1 | 2019 | 4 | 0.670 |
Why?
|
| Unconsciousness | 1 | 2019 | 17 | 0.670 |
Why?
|
| Neuropsychological Tests | 21 | 2022 | 927 | 0.660 |
Why?
|
| Sertraline | 2 | 2017 | 44 | 0.660 |
Why?
|
| Combat Disorders | 1 | 2019 | 22 | 0.660 |
Why?
|
| Dreams | 1 | 2019 | 24 | 0.650 |
Why?
|
| Adult | 36 | 2024 | 29355 | 0.650 |
Why?
|
| GABA Agents | 1 | 2019 | 21 | 0.650 |
Why?
|
| Head Injuries, Closed | 6 | 2006 | 44 | 0.640 |
Why?
|
| Acceptance and Commitment Therapy | 1 | 2020 | 40 | 0.640 |
Why?
|
| War-Related Injuries | 1 | 2018 | 1 | 0.620 |
Why?
|
| Psychotherapy | 5 | 2016 | 231 | 0.610 |
Why?
|
| Amygdala | 2 | 2017 | 81 | 0.610 |
Why?
|
| Valproic Acid | 1 | 2019 | 164 | 0.610 |
Why?
|
| Cross-Sectional Studies | 10 | 2024 | 3412 | 0.600 |
Why?
|
| Anxiety Disorders | 11 | 2021 | 685 | 0.600 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 94 | 0.600 |
Why?
|
| Alcoholism | 2 | 2019 | 230 | 0.600 |
Why?
|
| Chronic Pain | 1 | 2020 | 129 | 0.580 |
Why?
|
| Military Personnel | 2 | 2017 | 211 | 0.560 |
Why?
|
| Stress, Psychological | 2 | 2020 | 561 | 0.560 |
Why?
|
| Female | 67 | 2025 | 66288 | 0.560 |
Why?
|
| Double-Blind Method | 15 | 2021 | 1614 | 0.500 |
Why?
|
| Amyloid | 1 | 2015 | 65 | 0.490 |
Why?
|
| Dementia | 4 | 2011 | 450 | 0.490 |
Why?
|
| Models, Theoretical | 1 | 2017 | 357 | 0.480 |
Why?
|
| Comorbidity | 8 | 2020 | 1506 | 0.480 |
Why?
|
| Cerebrovascular Circulation | 3 | 2015 | 431 | 0.480 |
Why?
|
| Psychotropic Drugs | 2 | 2014 | 124 | 0.480 |
Why?
|
| Cognition | 6 | 2022 | 737 | 0.470 |
Why?
|
| Social Adjustment | 6 | 2010 | 85 | 0.460 |
Why?
|
| Iraq War, 2003-2011 | 4 | 2024 | 126 | 0.460 |
Why?
|
| Epilepsy | 1 | 2022 | 867 | 0.450 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2014 | 1241 | 0.440 |
Why?
|
| Polysomnography | 2 | 2025 | 142 | 0.440 |
Why?
|
| Apathy | 3 | 2022 | 9 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2021 | 1096 | 0.420 |
Why?
|
| Afghan Campaign 2001- | 3 | 2019 | 117 | 0.400 |
Why?
|
| Problem Solving | 4 | 2016 | 63 | 0.400 |
Why?
|
| Skin | 1 | 2015 | 511 | 0.390 |
Why?
|
| Case-Control Studies | 9 | 2020 | 3261 | 0.390 |
Why?
|
| Alzheimer Disease | 8 | 2011 | 786 | 0.390 |
Why?
|
| Oxygen | 1 | 2015 | 552 | 0.380 |
Why?
|
| Aggression | 4 | 2024 | 224 | 0.380 |
Why?
|
| Mental Competency | 1 | 2011 | 51 | 0.380 |
Why?
|
| Huntington Disease | 5 | 2014 | 143 | 0.360 |
Why?
|
| Pilot Projects | 3 | 2025 | 1396 | 0.360 |
Why?
|
| Diagnosis, Differential | 9 | 2019 | 1883 | 0.360 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2010 | 12 | 0.340 |
Why?
|
| Limbic System | 1 | 2010 | 22 | 0.340 |
Why?
|
| Treatment Outcome | 16 | 2022 | 12264 | 0.340 |
Why?
|
| Affective Symptoms | 1 | 2010 | 60 | 0.340 |
Why?
|
| Transcranial Direct Current Stimulation | 2 | 2020 | 13 | 0.340 |
Why?
|
| Emotions | 4 | 2018 | 365 | 0.330 |
Why?
|
| Statistics as Topic | 1 | 2010 | 252 | 0.320 |
Why?
|
| Follow-Up Studies | 13 | 2016 | 5094 | 0.310 |
Why?
|
| Severity of Illness Index | 15 | 2020 | 2885 | 0.300 |
Why?
|
| Brain Mapping | 5 | 2015 | 396 | 0.300 |
Why?
|
| Antidepressive Agents, Second-Generation | 4 | 2016 | 36 | 0.300 |
Why?
|
| Family Health | 1 | 2009 | 259 | 0.300 |
Why?
|
| Stroke Rehabilitation | 4 | 2013 | 59 | 0.300 |
Why?
|
| Motivation | 1 | 2010 | 315 | 0.290 |
Why?
|
| International Classification of Diseases | 2 | 2024 | 90 | 0.280 |
Why?
|
| Fear | 2 | 2021 | 201 | 0.280 |
Why?
|
| Anxiety | 3 | 2021 | 966 | 0.280 |
Why?
|
| Activities of Daily Living | 9 | 2013 | 404 | 0.270 |
Why?
|
| Bipolar Disorder | 4 | 2017 | 350 | 0.270 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 9 | 2011 | 211 | 0.260 |
Why?
|
| Memory Disorders | 2 | 2017 | 236 | 0.260 |
Why?
|
| Electric Stimulation Therapy | 2 | 2004 | 100 | 0.260 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2021 | 100 | 0.250 |
Why?
|
| Alcohol-Related Disorders | 1 | 2005 | 34 | 0.240 |
Why?
|
| Pyrrolidinones | 3 | 2010 | 17 | 0.240 |
Why?
|
| Behavior, Animal | 2 | 2018 | 492 | 0.240 |
Why?
|
| Cognitive Dysfunction | 2 | 2021 | 231 | 0.240 |
Why?
|
| Multiple Trauma | 2 | 2021 | 64 | 0.240 |
Why?
|
| Statistics, Nonparametric | 5 | 2012 | 424 | 0.230 |
Why?
|
| Agnosia | 3 | 2010 | 6 | 0.220 |
Why?
|
| Young Adult | 7 | 2020 | 8953 | 0.220 |
Why?
|
| Prospective Studies | 8 | 2024 | 6087 | 0.220 |
Why?
|
| Gulf War | 1 | 2023 | 8 | 0.220 |
Why?
|
| Aspartic Acid | 3 | 2014 | 75 | 0.210 |
Why?
|
| Positron-Emission Tomography | 3 | 2014 | 295 | 0.210 |
Why?
|
| Aphasia | 1 | 2022 | 14 | 0.210 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2014 | 139 | 0.210 |
Why?
|
| Neurocognitive Disorders | 2 | 1993 | 67 | 0.200 |
Why?
|
| Surveys and Questionnaires | 5 | 2024 | 3711 | 0.200 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2014 | 579 | 0.200 |
Why?
|
| Autonomic Nervous System | 2 | 2015 | 45 | 0.200 |
Why?
|
| Neurologic Examination | 8 | 2014 | 195 | 0.200 |
Why?
|
| Reading | 2 | 2014 | 80 | 0.190 |
Why?
|
| Hippocampus | 2 | 2007 | 827 | 0.190 |
Why?
|
| Extinction, Psychological | 1 | 2021 | 23 | 0.190 |
Why?
|
| Vagus Nerve | 1 | 2022 | 45 | 0.190 |
Why?
|
| Attention | 2 | 2022 | 197 | 0.190 |
Why?
|
| Geriatric Assessment | 3 | 2011 | 173 | 0.190 |
Why?
|
| Factor Analysis, Statistical | 2 | 2018 | 235 | 0.190 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2023 | 342 | 0.190 |
Why?
|
| Rivastigmine | 1 | 2021 | 17 | 0.190 |
Why?
|
| Temporal Lobe | 2 | 2000 | 115 | 0.180 |
Why?
|
| Sleep Wake Disorders | 2 | 2021 | 179 | 0.180 |
Why?
|
| Regression Analysis | 4 | 2017 | 773 | 0.180 |
Why?
|
| Prevalence | 5 | 2020 | 2428 | 0.180 |
Why?
|
| Risk Factors | 6 | 2015 | 10121 | 0.180 |
Why?
|
| Language Tests | 1 | 2000 | 24 | 0.180 |
Why?
|
| Memory, Short-Term | 1 | 2022 | 139 | 0.180 |
Why?
|
| Disability Evaluation | 2 | 2011 | 193 | 0.180 |
Why?
|
| Longitudinal Studies | 4 | 2018 | 1330 | 0.180 |
Why?
|
| Phonetics | 1 | 2000 | 41 | 0.180 |
Why?
|
| United States | 4 | 2024 | 10755 | 0.170 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 6442 | 0.170 |
Why?
|
| Recovery of Function | 3 | 2013 | 440 | 0.170 |
Why?
|
| Intelligence | 1 | 2000 | 98 | 0.170 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2014 | 290 | 0.170 |
Why?
|
| Cluster Headache | 1 | 1999 | 2 | 0.170 |
Why?
|
| Age of Onset | 3 | 2011 | 582 | 0.160 |
Why?
|
| Alcohol Deterrents | 1 | 2019 | 12 | 0.160 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 870 | 0.160 |
Why?
|
| Self Administration | 1 | 2019 | 43 | 0.160 |
Why?
|
| Personality Inventory | 4 | 2009 | 166 | 0.160 |
Why?
|
| Psychopharmacology | 1 | 2019 | 7 | 0.160 |
Why?
|
| Naltrexone | 1 | 2019 | 69 | 0.160 |
Why?
|
| Injury Severity Score | 2 | 2012 | 225 | 0.160 |
Why?
|
| Electroconvulsive Therapy | 2 | 2014 | 68 | 0.160 |
Why?
|
| Substance-Related Disorders | 2 | 2014 | 458 | 0.160 |
Why?
|
| Point Mutation | 1 | 2000 | 348 | 0.150 |
Why?
|
| Glasgow Coma Scale | 5 | 2005 | 203 | 0.150 |
Why?
|
| Age Factors | 3 | 2017 | 2812 | 0.150 |
Why?
|
| Recurrence | 2 | 2019 | 1423 | 0.150 |
Why?
|
| Nortriptyline | 3 | 2011 | 6 | 0.150 |
Why?
|
| Prefrontal Cortex | 2 | 2014 | 177 | 0.150 |
Why?
|
| Risk | 1 | 2020 | 748 | 0.150 |
Why?
|
| Fluoxetine | 3 | 2011 | 43 | 0.150 |
Why?
|
| Neurofeedback | 1 | 2017 | 5 | 0.150 |
Why?
|
| Motor Skills | 1 | 2018 | 83 | 0.140 |
Why?
|
| Spatial Memory | 1 | 2017 | 37 | 0.140 |
Why?
|
| Membrane Glycoproteins | 1 | 2020 | 412 | 0.140 |
Why?
|
| Pain Management | 1 | 2019 | 181 | 0.140 |
Why?
|
| Executive Function | 3 | 2013 | 106 | 0.140 |
Why?
|
| Denmark | 1 | 2016 | 34 | 0.140 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 63 | 0.130 |
Why?
|
| Cerebral Hemorrhage | 1 | 2018 | 144 | 0.130 |
Why?
|
| Models, Statistical | 3 | 2011 | 472 | 0.130 |
Why?
|
| Hospitals, University | 1 | 2016 | 97 | 0.130 |
Why?
|
| Encephalitis | 1 | 2017 | 109 | 0.130 |
Why?
|
| Osteoarthritis, Knee | 1 | 2019 | 244 | 0.130 |
Why?
|
| Atrophy | 3 | 2006 | 234 | 0.130 |
Why?
|
| Time Perception | 1 | 2015 | 11 | 0.130 |
Why?
|
| Connectome | 1 | 2017 | 99 | 0.120 |
Why?
|
| Pituitary-Adrenal System | 1 | 2015 | 36 | 0.120 |
Why?
|
| Mutation, Missense | 1 | 2000 | 863 | 0.120 |
Why?
|
| Language | 3 | 2022 | 204 | 0.120 |
Why?
|
| Prognosis | 5 | 2015 | 4548 | 0.120 |
Why?
|
| Arousal | 1 | 2015 | 81 | 0.120 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2015 | 65 | 0.120 |
Why?
|
| Interpersonal Relations | 2 | 2013 | 228 | 0.120 |
Why?
|
| Psychometrics | 5 | 2009 | 673 | 0.120 |
Why?
|
| Motor Activity | 2 | 2017 | 524 | 0.110 |
Why?
|
| Semantics | 1 | 2014 | 18 | 0.110 |
Why?
|
| Linear Models | 2 | 2013 | 671 | 0.110 |
Why?
|
| Neuropsychiatry | 1 | 2014 | 12 | 0.110 |
Why?
|
| Gyrus Cinguli | 1 | 2015 | 113 | 0.110 |
Why?
|
| Dominance, Cerebral | 2 | 2010 | 55 | 0.110 |
Why?
|
| Quality of Life | 1 | 2023 | 1950 | 0.110 |
Why?
|
| Social Perception | 1 | 2014 | 57 | 0.110 |
Why?
|
| Comprehension | 1 | 2014 | 77 | 0.110 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2014 | 83 | 0.110 |
Why?
|
| Nootropic Agents | 2 | 2010 | 27 | 0.110 |
Why?
|
| Hospitals, Veterans | 1 | 2015 | 355 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 158 | 0.110 |
Why?
|
| Apolipoproteins E | 1 | 2014 | 190 | 0.100 |
Why?
|
| Brain Injury, Chronic | 2 | 2004 | 21 | 0.100 |
Why?
|
| Impulsive Behavior | 1 | 2014 | 144 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2015 | 300 | 0.100 |
Why?
|
| Time Factors | 6 | 2018 | 6252 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2000 | 1522 | 0.100 |
Why?
|
| Psychomotor Performance | 2 | 2004 | 182 | 0.100 |
Why?
|
| Electromagnetic Fields | 2 | 2002 | 26 | 0.100 |
Why?
|
| Aging | 1 | 1999 | 1197 | 0.100 |
Why?
|
| Heart Rate | 2 | 2017 | 590 | 0.090 |
Why?
|
| Brain Ischemia | 2 | 2013 | 258 | 0.090 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2012 | 238 | 0.090 |
Why?
|
| Nerve Net | 2 | 2010 | 239 | 0.090 |
Why?
|
| Movement Disorders | 1 | 2013 | 221 | 0.090 |
Why?
|
| Perceptual Disorders | 1 | 2010 | 3 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 443 | 0.090 |
Why?
|
| Frontal Lobe | 3 | 2007 | 111 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 339 | 0.090 |
Why?
|
| Argentina | 3 | 2011 | 52 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 1415 | 0.080 |
Why?
|
| Registries | 1 | 2016 | 1411 | 0.080 |
Why?
|
| Family | 1 | 2013 | 567 | 0.080 |
Why?
|
| Iowa | 2 | 2013 | 13 | 0.080 |
Why?
|
| Neuroimaging | 1 | 2012 | 339 | 0.080 |
Why?
|
| Choline | 1 | 2010 | 54 | 0.080 |
Why?
|
| Expressed Emotion | 1 | 2009 | 9 | 0.080 |
Why?
|
| Glucose | 1 | 2014 | 886 | 0.080 |
Why?
|
| Thalamus | 2 | 2010 | 85 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2017 | 16214 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2015 | 1007 | 0.080 |
Why?
|
| Drug Resistance | 1 | 2009 | 256 | 0.080 |
Why?
|
| Dysthymic Disorder | 1 | 2008 | 6 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2014 | 1329 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2009 | 214 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1244 | 0.070 |
Why?
|
| Acute Disease | 3 | 2018 | 1098 | 0.070 |
Why?
|
| Brain Chemistry | 1 | 2007 | 123 | 0.070 |
Why?
|
| Dangerous Behavior | 1 | 2007 | 11 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2009 | 165 | 0.070 |
Why?
|
| Animals | 4 | 2021 | 34151 | 0.070 |
Why?
|
| Adolescent | 6 | 2020 | 19307 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2024 | 2870 | 0.070 |
Why?
|
| Delusions | 1 | 2006 | 17 | 0.070 |
Why?
|
| Organ Size | 1 | 2006 | 435 | 0.060 |
Why?
|
| Putamen | 1 | 2005 | 19 | 0.060 |
Why?
|
| Intelligence Tests | 2 | 2004 | 57 | 0.060 |
Why?
|
| Employment | 1 | 2005 | 67 | 0.060 |
Why?
|
| Affect | 3 | 2009 | 159 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2005 | 3367 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2005 | 157 | 0.060 |
Why?
|
| Anger | 1 | 2024 | 30 | 0.060 |
Why?
|
| Laughter | 1 | 2004 | 10 | 0.060 |
Why?
|
| Crying | 1 | 2004 | 12 | 0.060 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2004 | 32 | 0.060 |
Why?
|
| Brain Infarction | 1 | 2004 | 30 | 0.060 |
Why?
|
| Causality | 1 | 2004 | 83 | 0.060 |
Why?
|
| Verbal Learning | 1 | 2004 | 67 | 0.050 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2003 | 26 | 0.050 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2003 | 27 | 0.050 |
Why?
|
| Brain Damage, Chronic | 2 | 2013 | 30 | 0.050 |
Why?
|
| Basal Ganglia | 3 | 2010 | 55 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2005 | 257 | 0.050 |
Why?
|
| Violence | 1 | 2024 | 116 | 0.050 |
Why?
|
| Language Therapy | 1 | 2022 | 3 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 4725 | 0.050 |
Why?
|
| Transdermal Patch | 1 | 2021 | 8 | 0.050 |
Why?
|
| Epidemiologic Measurements | 1 | 2000 | 3 | 0.050 |
Why?
|
| Mental Health | 1 | 2024 | 346 | 0.050 |
Why?
|
| Wechsler Scales | 1 | 2000 | 21 | 0.050 |
Why?
|
| Protons | 2 | 2014 | 91 | 0.040 |
Why?
|
| Research Design | 1 | 2024 | 688 | 0.040 |
Why?
|
| Presenilin-1 | 1 | 2000 | 53 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 762 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2003 | 1478 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 341 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 1999 | 46 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 1316 | 0.040 |
Why?
|
| Brain Waves | 1 | 2020 | 47 | 0.040 |
Why?
|
| Tomography, Emission-Computed | 1 | 1999 | 43 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 343 | 0.040 |
Why?
|
| Disease Progression | 3 | 2013 | 2037 | 0.040 |
Why?
|
| Brazil | 1 | 2018 | 122 | 0.040 |
Why?
|
| Incidence | 1 | 2005 | 3078 | 0.040 |
Why?
|
| Gliosis | 1 | 2017 | 32 | 0.040 |
Why?
|
| Interview, Psychological | 1 | 2018 | 98 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2000 | 788 | 0.040 |
Why?
|
| Serotonin | 1 | 1999 | 232 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 243 | 0.040 |
Why?
|
| Maze Learning | 1 | 2017 | 128 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 1994 | 2079 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 1289 | 0.030 |
Why?
|
| Microglia | 1 | 2017 | 96 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 687 | 0.030 |
Why?
|
| Memory | 1 | 1999 | 363 | 0.030 |
Why?
|
| Pedigree | 1 | 2000 | 1596 | 0.030 |
Why?
|
| Personality Assessment | 2 | 2009 | 105 | 0.030 |
Why?
|
| Models, Animal | 1 | 2017 | 467 | 0.030 |
Why?
|
| Patient Safety | 1 | 2020 | 399 | 0.030 |
Why?
|
| Astrocytes | 1 | 2017 | 252 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 1101 | 0.030 |
Why?
|
| Dermatan Sulfate | 1 | 2013 | 4 | 0.030 |
Why?
|
| Chondroitin Sulfates | 1 | 2013 | 14 | 0.030 |
Why?
|
| Heparitin Sulfate | 1 | 2013 | 20 | 0.030 |
Why?
|
| Trinucleotide Repeats | 1 | 2014 | 109 | 0.030 |
Why?
|
| Social Participation | 1 | 2013 | 20 | 0.030 |
Why?
|
| Glasgow Outcome Scale | 1 | 2013 | 46 | 0.030 |
Why?
|
| Social Environment | 1 | 2014 | 119 | 0.030 |
Why?
|
| Trauma Severity Indices | 1 | 1993 | 88 | 0.030 |
Why?
|
| Forecasting | 1 | 1994 | 353 | 0.030 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 1993 | 42 | 0.030 |
Why?
|
| Logistic Models | 2 | 2008 | 1801 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 269 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2017 | 868 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 725 | 0.020 |
Why?
|
| Functional Laterality | 2 | 2008 | 182 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2011 | 59 | 0.020 |
Why?
|
| Australia | 1 | 2011 | 138 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1993 | 228 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1014 | 0.020 |
Why?
|
| Mice | 2 | 2018 | 17751 | 0.020 |
Why?
|
| Phenotype | 1 | 2000 | 4254 | 0.020 |
Why?
|
| Awareness | 1 | 2010 | 80 | 0.020 |
Why?
|
| Hospitalization | 1 | 2018 | 1752 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1086 | 0.020 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2008 | 61 | 0.020 |
Why?
|
| Internal-External Control | 1 | 2009 | 75 | 0.020 |
Why?
|
| Italy | 1 | 2008 | 113 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2013 | 581 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2008 | 44 | 0.020 |
Why?
|
| Facial Expression | 1 | 2008 | 28 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1993 | 2040 | 0.020 |
Why?
|
| Creatine | 1 | 2007 | 41 | 0.020 |
Why?
|
| Glutamates | 1 | 2007 | 69 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 4351 | 0.020 |
Why?
|
| Demography | 1 | 2008 | 239 | 0.020 |
Why?
|
| Self Concept | 1 | 2008 | 156 | 0.020 |
Why?
|
| Capgras Syndrome | 1 | 2006 | 3 | 0.020 |
Why?
|
| Parents | 1 | 2013 | 1039 | 0.020 |
Why?
|
| Caudate Nucleus | 1 | 2005 | 35 | 0.020 |
Why?
|
| Dementia, Vascular | 1 | 2005 | 16 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 462 | 0.010 |
Why?
|
| Models, Psychological | 1 | 2005 | 138 | 0.010 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2005 | 74 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1688 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 586 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2003 | 225 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2000 | 76 | 0.010 |
Why?
|
| Caregivers | 1 | 2006 | 578 | 0.010 |
Why?
|
| Child | 1 | 2013 | 24476 | 0.010 |
Why?
|